country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-183786

Copy Link Print Information

Anticancer agent 327

Anticancer agent 327, a fluorescent Andrographolide (HY-N0191) derivative, is an NF-κB p50 inhibitor. Anticancer agent 327 covalently binds to the p50 subunit of NF-κB. Anticancer agent 327 reduces levels of multiple oncogenic p53 proteins via the autophagy/lysosome pathway. Anticancer agent 327 can be used for the research of pancreatic ductal adenocarcinoma (Ex/Em = 488/515 nm)^[1].

For research use only. We do not sell to patients.

Formula: C₂₉H₃₆N₄O₈
Molecular Weight:568.62

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Anticancer agent 327 Chemical Structure

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

All NF-κB Isoforms :

In Vitro

Anticancer agent 327 (Compound 4) (1-30 μM; 48 h) potently reduces viability of PANC-1 and MIA PaCa-2 PDAC cells with IC₅₀ values of 9.94 μM and 25.30 μM, respectively^[1].
Anticancer agent 327 (1-30 μM; 2-24 h) significantly reduces levels of oncogenic p53^R273H in PANC-1 cells and p53^R248W in MIA PaCa-2 cells in a concentration- and time-dependent manner^[1].
Anticancer agent 327 (10 μM; 24 h) reduces oncogenic p53^R273H protein levels in PANC-1 cells primarily through the autophagy pathway^[1].
Anticancer agent 327 (1-30 μM; 24 h) potently inhibits long-term proliferation of PANC-1, MIA PaCa-2, and KPC PDAC cells, with the greatest activity against PANC-1 cells^[1].
Anticancer agent 327 (1-30 μM; 10-24 h) suppresses migration of PANC-1, MIA PaCa-2, and KPC PDAC cells in a concentration-dependent manner, with the strongest activity against KPC cells^[1].
Anticancer agent 327 (5-10 μM; 12 h) downregulates transcription of multiple cancer-related genes downstream of oncogenic TP53^R273H, without altering TP53 mRNA levels^[1].
Anticancer agent 327 (6 μM; 5 min-48 h) is rapidly taken up by PANC-1 cells, with detectable fluorescent signals within 5 min, and remains stably retained for at least 48 h^[1].
Anticancer agent 327 (1-10 μM; 1 h at 25 °C) covalently binds to the NF-κB p50 subunit in vitro in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human pancreatic ductal adenocarcinoma (PDAC) cell lines PANC-1 (p53^R273H), MIA PaCa-2 (p53^R248W)
Concentration:

1 μM; 3 μM; 10 μM; 30 μM
Incubation Time:

48 h
Result:

Exhibited concentration-dependent cytotoxicity in both cell lines.
Had an IC₅₀ of 9.94 μM in PANC-1 cells, with significant viability reduction at all tested concentrations.
Had an IC₅₀ of 25.30 μM in MIA PaCa-2 cells, with significant viability reduction at 30 μM.

Western Blot Analysis^[1]

Cell Line:

human PDAC PANC-1 (p53^R273H) cells
Concentration:

1 μM; 3 μM; 5 μM; 10 μM; 20 μM
Incubation Time:

2 h; 6 h; 12 h; 24 h
Result:

Significantly upregulated the autophagy marker LC3-II.
Caused time-dependent and concentration-dependent reduction of p53^R273H.

Western Blot Analysis^[1]

Cell Line:

MIA PaCa-2 (p53^R248W)
Concentration:

3 μM; 5 μM; 10 μM; 20 μM; 30 μM
Incubation Time:

2 h; 6 h; 12 h; 24 h
Result:

Caused time-dependent and concentration-dependent reduction of p53^R248W levels.

Cell Proliferation Assay^[1]

Cell Line:

human PDAC cell lines PANC-1 (p53^R273H), MIA PaCa-2 (p53^R248W), mouse PDAC cell line KPC (p53^R172H)
Concentration:

1 μM; 3 μM; 5 μM; 10 μM; 30 μM
Incubation Time:

24 h
Result:

Significantly suppressed colony formation in all three cell lines in a concentration-dependent manner.
Showed the strongest effect on colony formation in PANC-1 cells.

Cell Migration Assay ^[1]

Cell Line:

human PDAC cell lines PANC-1 (p53^R273H), MIA PaCa-2 (p53^R248W), mouse PDAC cell line KPC (p53^R172H)
Concentration:

1 μM; 3 μM; 10 μM; 30 μM
Incubation Time:

10 h; 12 h; 24 h
Result:

Suppressed migration of PANC-1 and KPC cells in a concentration-dependent manner, with no apparent cytotoxicity during the incubation period.
Reduced migration of MIA PaCa-2 cells only at 30 μM, with cytotoxicity observed at this concentration.
Caused greater suppression of migration in KPC cells than PANC-1 cells.

Real Time qPCR^[1]

Cell Line:

human PDAC PANC-1 (p53^R273H) cells
Concentration:

5 μM; 10 μM
Incubation Time:

12 h
Result:

Significantly reduced mRNA levels of CCNA2, PCNA, CXCL1, CXCL2, CXCL8, TIGAR, and MYC in a concentration-dependent manner.
Did not affect TP53 mRNA levels, indicating post-transcriptional regulation of p53^R273H.
Suppressed MYC expression, unlike andrographolide.

In Vivo

Anticancer agent 327 (Compound 4) (10-20 mg/kg; i.p.; every 2 days; 4 total doses) exhibits no observable in vivo toxicity in 4-week-old immunocompetent C57BL/6 mice at the tested dosing regimen^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male; 4 weeks old)^[1]
Dosage:

10 mg/kg; 20 mg/kg
Administration:

i.p.; every 2 days; 4 total doses
Result:

Did not affect the body weights of treated mice.
Showed no evident liver or kidney toxicity, as indicated by serum biochemical parameters and histological analyses of liver and kidney tissues.

Chemical Information

Molecular Weight 568.62
Formula C₂₉H₃₆N₄O₈
SMILES

CN(CC1OC[C@]([C@](CCC([C@H]2C/C=C3C(OC[C@H]/3O)=O)=C)([H])[C@@]2(C)CC4)(C)[C@@H]4O1)C5=CC=C([N+]([O-])=O)C6=NON=C56
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Li YR, et al. Design, synthesis, and evaluation of novel andrographolide derivatives as anti-pancreatic cancer therapeutics. Bioorg Chem. 2026;178:109946. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock